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Background. As the threat of multidrug-resistant Gram-negative (MDRGN) bacteria rises, recognizing children at high risk of bloodstream infections with bacteria resistant to commonly prescribed empiric antibiotics is critical. We developed a decision tree to predict which pediatric bloodstream infections were due to MDRGN bacteria resistant to cefepime or piperacillin-tazobactam, commonly prescribed empiric antibiotics.
Methods. We conducted a longitudinal retrospective cohort study at the Children's Hospital of Pittsburgh including all admitted patients with a Gram-negative bloodstream infection from June 2009 to June 2015. Episodes of bloodstream infection were considered unique if at least 30 days had elapsed since the previous bloodstream infection. Logistic regression was performed to identify notable risk factors. A decision tree describing the risk of an MDRGN infection was developed using recursive partitioning based on clinical characteristics available at the time of presentation.
Results. Six hundred eighty-nine episodes of Gram-negative bloodstream infections occurred during the study period among 387 patients. Twenty-eight percent of infections were multidrug-resistant (MDR). The decision tree separated patients into higher or lower risk groups based on history of prior carbapenem treatment for seven or more days, having a prior MDR infection within 6 months, intestinal transplant status, age 3 years or older, and seven or more prior episodes of bacteremia. The sensitivity to classify high risk of MDR was 46% and the specificity was 92% based on leave one out cross validation. For patients who had more than one episode, 30% of initially non-MDR infections were subsequently MDR.
Conclusion. A decision tree using readily available clinical characteristics may be helpful to identify pediatric patients at higher risk of bloodstream infection due to an MDRGN organism resistant to common empirical antibiotic therapy. Thursday, October 4, 2018: 12:30 PM Background. Data on the impact of empiric febrile neutropenia (FN) guidelines on resistant bacteria in pediatric oncology patients are limited. We implemented a risk-stratified guideline for empiric FN antibiotics, limiting vancomycin use to high-risk patients for 48 hours if cultures were negative. Our aim was to assess the impact of this intervention on rates of vancomycin-resistant Enterococcus (VRE) and vancomycin use.
The Impact of a Revised Neutropenic Fever Guideline on VancomycinResistant Enterococcus Rates in Pediatric Oncology Patients
Methods. We conducted a retrospective, quasi-experimental study of oncology patients ≤ 18 years with FN admitted from 2010 to 2014. Microbiologic data and inpatient antibiotic use were obtained by chart review. Risk strata incorporated diagnosis, chemotherapy phase, Down syndrome, septic shock, and typhlitis. The primary outcome was VRE incidence; all VRE isolates were included but active surveillance
